BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 24793156)

  • 1. [Current methods to detect EGFR gene mutations as predictive factor for targeted therapies in non-small cell lung cancer - is there a "golden standard" in diagnostics?].
    Skroński M; Szpechciński A; Chorostowska-Wynimko J
    Pneumonol Alergol Pol; 2014; 82(3):311-22. PubMed ID: 24793156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy).
    de Biase D; Visani M; Malapelle U; Simonato F; Cesari V; Bellevicine C; Pession A; Troncone G; Fassina A; Tallini G
    PLoS One; 2013; 8(12):e83607. PubMed ID: 24376723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas
    Satouchi M; Tanaka H; Yoshioka H; Shimokawaji T; Mizuno K; Takeda K; Yoshino I; Seto T; Kurata T; Tashiro N; Hagiwara K
    Lung Cancer; 2017 Sep; 111():190-194. PubMed ID: 28838392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC).
    Reynolds JP; Tubbs RR; Minca EC; MacNamara S; Almeida FA; Ma PC; Pennell NA; Cicenia JC
    Lung Cancer; 2014 Nov; 86(2):158-63. PubMed ID: 25263855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next-generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice.
    Moore DA; Balbi K; Ingham A; Arkenau HT; Bennett P
    J Clin Pathol; 2018 Nov; 71(11):1001-1006. PubMed ID: 30054375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of epidermal growth factor receptor mutation in non-small-cell lung carcinoma using cytological and histological specimens.
    Xu H; Sun W; Zhang G; Cheng Y
    J BUON; 2015; 20(1):142-5. PubMed ID: 25778309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.
    Zhao X; Han RB; Zhao J; Wang J; Yang F; Zhong W; Zhang L; Li LY; Wang MZ
    Respiration; 2013; 85(2):119-25. PubMed ID: 22797485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer.
    Peters MJ; Bowden JJ; Carpenter P; Lewis J; Solomon B
    Intern Med J; 2014 Jun; 44(6):575-80. PubMed ID: 24720523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Detection of epidermal growth factor receptor mutations in non-small cell lung cancer by real-time PCR using TaqMan-MGB probes].
    Zhou CC; Zhou SW; Pan H; Su B; Gao ZQ
    Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):119-23. PubMed ID: 17645848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct sequencing in cytological specimens as a useful strategy for detecting EGFR mutations in non-small cell lung cancer patients.
    Cho MC; Choi CM; Kim S; Jang S; Jang S; Park CJ; Chi HS; Peyton MJ; Lee W; Chun S; Kim SW; Min WK
    Clin Chem Lab Med; 2011 Sep; 50(3):565-72. PubMed ID: 21899495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of EGFR mutations in patients with non-small cell lung cancer by high resolution melting. Comparison with other methods.
    Martínez-Carretero C; Pascual FI; Rus A; Bernardo I
    Clin Chem Lab Med; 2017 Oct; 55(12):1970-1978. PubMed ID: 28432840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.
    Liang Z; Cheng Y; Chen Y; Hu Y; Liu WP; Lu Y; Wang J; Wang Y; Wu G; Ying JM; Zhang HL; Zhang XC; Wu YL
    Cancer Lett; 2017 Sep; 403():186-194. PubMed ID: 28642172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Research Advancement on EGFR Mutation Detection of Cell-free DNA and Tumor Cell in Peripheral Blood of Patients with Non-small Cell Lung Cancer].
    Zhang Y; Xu Y; Wang M
    Zhongguo Fei Ai Za Zhi; 2016 Nov; 19(11):766-772. PubMed ID: 27866520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1).
    Beau-Faller M; Degeorges A; Rolland E; Mounawar M; Antoine M; Poulot V; Mauguen A; Barbu V; Coulet F; Prétet JL; Bièche I; Blons H; Boyer JC; Buisine MP; de Fraipont F; Lizard S; Olschwang S; Saulnier P; Prunier-Mirebeau D; Richard N; Danel C; Brambilla E; Chouaid C; Zalcman G; Hainaut P; Michiels S; Cadranel J
    J Thorac Oncol; 2011 Jun; 6(6):1006-15. PubMed ID: 21532509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer.
    Lozano MD; Labiano T; Echeveste J; Gurpide A; Martín-Algarra S; Zhang G; Sharma A; Palma JF
    Cancer Cytopathol; 2015 Apr; 123(4):230-6. PubMed ID: 25529460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens.
    Billah S; Stewart J; Staerkel G; Chen S; Gong Y; Guo M
    Cancer Cytopathol; 2011 Apr; 119(2):111-7. PubMed ID: 21400670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
    Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
    Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating plasma microRNAs as potential markers to identify EGFR mutation status and to monitor epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with advanced non-small cell lung cancer.
    Qu L; Li L; Zheng X; Fu H; Tang C; Qin H; Li X; Wang H; Li J; Wang W; Yang S; Wang L; Zhao G; Lv P; Lei Y; Zhang M; Gao H; Song S; Liu X
    Oncotarget; 2017 Jul; 8(28):45807-45824. PubMed ID: 28496005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Detection of epidermal growth factor receptor mutations in non-small-cell lung carcinoma by direct sequencing and correlations with clinicopathological characteristics and sample types].
    Sun MH; Yang F; Shen L; Zhang L; Chen Y; Cai X; Zhu XL; Zhou XY
    Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):655-9. PubMed ID: 22321541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma.
    Rachiglio AM; Esposito Abate R; Sacco A; Pasquale R; Fenizia F; Lambiase M; Morabito A; Montanino A; Rocco G; Romano C; Nappi A; Iaffaioli RV; Tatangelo F; Botti G; Ciardiello F; Maiello MR; De Luca A; Normanno N
    Oncotarget; 2016 Oct; 7(41):66595-66605. PubMed ID: 27448974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.